Approved indication: Dayvigo is approved to treat insomnia in adults who have difficulty falling asleep, staying asleep, or both.

Off-label uses: Clinicians may occasionally use lemborexant off label for certain circadian rhythm–related sleep problems (such as irregular sleep–wake patterns in dementia), but these uses are not FDA-approved and the evidence is still limited, so they are reserved for select situations under specialist guidance.

Efficacy and onset: In clinical trials, many patients showed improvements in time to fall asleep and total sleep time from the first few nights of treatment, with benefits maintained over months when taken regularly.

Typical outcomes: People commonly experience falling asleep faster, fewer or shorter nighttime awakenings, and better overall sleep quality, though some may still have residual insomnia symptoms or daytime sleepiness.

Comparison with similar drugs: Compared with older benzodiazepine and “Z‑drug” hypnotics, Dayvigo and other dual orexin receptor antagonists tend to provide strong sleep-maintenance benefits with a lower risk of dependence, withdrawal, or rebound insomnia, and they may be better tolerated in many older adults, though individual responses vary.

Standard adult dosing: The usual starting dose is 5 mg taken by mouth once per night, immediately before going to bed, with at least 7 hours available before planned awakening; if needed and well tolerated, this may be increased to a maximum of 10 mg once nightly.

How to take it: Swallow the tablet whole with or without food, but avoid taking it with or right after a heavy meal because this can delay the onset of sleep; take it only on nights when you are going to bed and can stay in bed for a full night, and never more than one dose in the same night.

Dose adjustments: In adults with moderate liver impairment or those taking weak CYP3A inhibitors, the maximum recommended dose is 5 mg nightly; Dayvigo should not be used with strong or moderate CYP3A inhibitors or CYP3A inducers and is not recommended in severe liver impairment.

Special considerations: No routine dose adjustment is usually required for kidney impairment, but older adults and people at higher risk of falls or daytime sleepiness often start and remain at 5 mg.

Missed dose: If you miss your usual bedtime or do not have at least 7 hours left to sleep, skip the dose; do not take an extra dose later in the night or double the next dose to make up for it.

Overdose: Taking more than prescribed can cause profound drowsiness, confusion, coordination problems, or breathing issues; if an overdose is suspected, seek emergency medical care or contact poison control right away and do not drive or operate machinery.

Common side effects: The most frequent effect is next‑day sleepiness or fatigue, especially at the 10 mg dose or if you do not get a full 7 hours of sleep; headache, abnormal dreams, and mild dizziness can also occur, usually starting with the first doses and often lessening over time.

Serious or rare reactions: Seek immediate medical attention for complex sleep behaviors (such as sleepwalking, sleep‑driving, or eating while not fully awake), new or worsening depression, suicidal thoughts, confusion, hallucinations, severe anxiety or agitation, sudden muscle weakness, or trouble moving or speaking upon waking (sleep paralysis or cataplexy‑like episodes), or any signs of an allergic reaction like rash, swelling, or difficulty breathing.

Warnings and precautions: Dayvigo must not be used in people with narcolepsy and should be used cautiously in those with depression or other mental health conditions, a history of substance or alcohol misuse, breathing problems such as sleep apnea or COPD, balance problems or frequent falls, or liver impairment.

Pregnancy and breastfeeding: Because human data are limited, use during pregnancy or while breastfeeding is generally considered only if the potential benefit clearly outweighs possible risks; if used while breastfeeding, infants should be observed for unusual sleepiness or poor feeding.

Age and organ function: Dayvigo is approved for adults 18 years and older; extra caution is advised with the 10 mg dose in adults 65 years and older, the maximum recommended dose is 5 mg nightly in moderate liver impairment, it is not recommended in severe liver disease, and no routine dose change is usually needed in kidney impairment.

Comparative safety: Compared with many benzodiazepines and Z‑drugs, Dayvigo generally has a lower risk of dependence, withdrawal, and rebound insomnia, but it is still a Schedule IV controlled substance that can impair driving and increase fall risk, particularly at higher doses or in combination with alcohol or other sedating drugs.

Reporting and safety updates: Side effects can be reported to a healthcare professional and to the FDA MedWatch program (for example by calling 1‑800‑FDA‑1088), and up‑to‑date safety communications are available through the FDA, the manufacturer’s website, and the latest prescribing information.

Prescription and OTC drug interactions: Avoid using Dayvigo with strong or moderate CYP3A inhibitors (such as certain azole antifungals, macrolide antibiotics, some antiarrhythmics, and HIV protease inhibitors) or CYP3A inducers (such as some seizure medicines, rifampin, and St. John’s wort), because they can greatly increase side effects or reduce effectiveness; use great caution when combining with other central nervous system depressants, including benzodiazepines, opioids, other sleep aids, sedating antihistamines, or muscle relaxants.

Supplements and foods: Herbal products that affect CYP3A, especially St. John’s wort, may make Dayvigo less effective, while grapefruit or grapefruit juice may raise drug levels and side effects, so all vitamins, herbs, and supplements should be reviewed with a clinician.

Alcohol and activities: Alcohol increases sedation and the risk of complex sleep behaviors, so it should not be used on the same evening as Dayvigo, and you should not drive or do tasks that require full alertness the next morning until you know how the medicine affects you.

Conditions requiring extra caution: Dayvigo is contraindicated in narcolepsy and should be used carefully or avoided in people with significant liver disease, untreated or severe sleep apnea or COPD, a history of complex sleep behaviors with other sleep medicines, depression or other mood disorders, or a history of substance or alcohol misuse.

Monitoring needs: Healthcare providers may monitor sleep patterns, daytime alertness, mood and suicidal thinking, fall risk (especially in older adults), and liver function or other labs when indicated, adjusting the dose or discontinuing the drug if concerns arise.

Q: How quickly will Dayvigo start helping me sleep?
A: Many people notice some improvement in falling or staying asleep within the first few nights, but full benefit can take several days to a few weeks of regular use while also practicing good sleep habits.

Q: Can I take Dayvigo every night for a long time?
A: Dayvigo has been studied for use over many months, and some people do take it long term, but your prescriber will usually reassess regularly and may try to use the lowest effective dose and combine it with non-drug treatments like cognitive behavioral therapy for insomnia.

Q: Is Dayvigo addictive or will I have withdrawal symptoms if I stop?
A: Dayvigo is a Schedule IV controlled medicine with some potential for misuse, but it appears to cause less physical dependence and withdrawal than many older sleeping pills, and most people can stop it without tapering under medical guidance, though insomnia may return if underlying sleep problems persist.

Q: Can I take Dayvigo with other sleep medicines or anxiety medications?
A: Combining Dayvigo with other sedatives, including many sleep, anxiety, pain, or allergy medicines, can greatly increase drowsiness, confusion, and fall risk, so you should not add or change any such medications without first discussing it with your prescriber.

Q: What should I do if Dayvigo is not working well enough?
A: If you still have significant trouble sleeping after several nights to a few weeks, talk with your clinician about checking your sleep schedule and habits, adjusting the dose or timing, or considering alternative treatments rather than taking extra doses on your own.

Storage: Store Dayvigo tablets at room temperature (about 68°F to 77°F), in the original container, tightly closed, away from moisture, heat, and light, and out of reach of children and pets.

Handling: Keep the bottle secure, do not share the medication with others, and do not use tablets that are damaged, discolored, or past their expiration date.

Disposal: Because Dayvigo is a controlled medicine, use a drug take-back program or authorized collection site when possible; if none is available, mix unused tablets with an undesirable substance (such as used coffee grounds or cat litter), seal in a bag or container, and place in the household trash unless your pharmacist or local guidelines recommend another method.